- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01245335
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)
Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-0012
- University Of Alabama
-
-
Arkansas
-
El Dorado, Arkansas, United States, 71730
- Medical Center of South Arkansas
-
-
California
-
Los Angeles, California, United States, 90033
- USC Keck School of Medicine
-
-
Florida
-
Orlando, Florida, United States, 32804
- Florida Hospital - Vascular Institute of Central Florida
-
Pensacola, Florida, United States, 32503
- Coastal Vascular & Interventional
-
Tampa, Florida, United States, 33606
- USF / Tampa General
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois-Chicago
-
Winfield, Illinois, United States, 60190
- Cadence Health, Central DuPage Hospital
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic
-
-
Maine
-
Portland, Maine, United States, 04102
- Maine Medical Ctr
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess
-
-
Missouri
-
Kansas City, Missouri, United States, 64116
- Kansas City Vascular
-
St. Louis, Missouri, United States, 63141
- Mercy Hospital
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Ctr
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Cooper University Hospital
-
Teaneck, New Jersey, United States, 07666
- Holy Name Medical Center
-
-
New York
-
Lake Success, New York, United States, 11042
- North Shore-Long Island Jewish
-
New York, New York, United States, 10025
- St. Luke's Roosevelt
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina At Chapel Hill
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
Lima, Ohio, United States, 45801
- Regional Infectious Disease and Infusion Ctr
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74135
- University of Oklahoma
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health Science University
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, United States, 29401
- Roper St Francis Medical Center
-
Greenville, South Carolina, United States, 29615
- Greenville Health System
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- University of Tennessee
-
-
Texas
-
Dallas, Texas, United States, 75226
- Baylor Medical Ctr
-
Houston, Texas, United States, 77030
- University of Texas - Houston Medical School
-
-
Washington
-
Vancouver, Washington, United States, 98682
- Peace Health Southwest Medical Center
-
-
West Virginia
-
Charleston, West Virginia, United States, 25304
- Charleston Area Medical Center Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient has Peripheral Arterial Occlusive Disease (PAOD) with clinical Rutherford Category 5 disease, as defined in the reporting standards adopted by the Society of Vascular Surgeons(table 1); Minor Tissue loss-focal gangrene with diffuse pedal ischemia
Patient meets at least one of the following diagnostic criteria in the study limb:
- Ankle artery occlusion pressure absolute ≤60 mmHg or ABI ≤0.6
- Toe artery occlusive pressure < 50mm Hg or TBI ≤0.6
There is no reasonable open surgical or endovascular revascularization option as determined by the treating vascular specialist. Factors that may contribute to the determination of inoperability may include:
- Anatomical considerations
- No outflow targets
- No appropriate conduit (i.e. vein for bypass)
Long segment occlusions or calcified lesions that predict poor outcome with endovascular approaches.
- High risk medical conditions i.e. Unstable cardiac disease.
- History of prior failed revascularization attempts
- The Patient's case was reviewed at the treating institution's Multidisciplinary Vascular Conference where the patient's status as a poor candidate for conventional therapies was confirmed.
- Age ≥18 years and ability to understand the planned treatment
- Subject has read and signed the IRB approved Informed Consent form
- Patients for whom the following medication(s) is prescribed must have a one month stable baseline therapy prior to enrollment: Plavix/asprin therapy, anticoagulation therapy, cholesterol lowering agent, and or blood pressure medication. If any of these medications are not prescribed notation of the reason for omission is to be provided.
- Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Creatinine ≤ 2.5 mg / dL, INR ≤ 1.6 unless on Coumadin, or PTT <1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR<1.6 at the time of randomization/surgery.
Exclusion Criteria:
- Life expectancy <6 months due to concomitant illnesses
- History of bone marrow diseases (especially NHL, MDS) that prohibit transplantation
- Terminal renal failure with existing dependence on dialysis or serum creatinine >2.5 mg/dL
- Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemocult unless follow-up studies reveal patient to be cancer free.
- Poorly controlled diabetes mellitus (HgbA1C>10%)
- Medical risk that precludes anesthesia (conscious sedation), or ASA Class 5
- Life-threatening complications of the ischemia necessitating immediate amputation
- Uncorrected occlusion of the common or external iliac artery on index side
- Absence of any pulsatile Doppler flow below the ankle.
- Extensive necrosis of the index limb or other conditions that make amputation inevitable (Rutherford Category 6).
- Ulceration with exposed bone proximal to the distal metatarsal heads (ie. heel or mid foot)
- Active clinical infection or infection being treated by antibiotics within one week of enrollment
- Treatment with immunosuppressant drugs (including Prednisone > 5 mg per day).
- Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method.
- Underwent a major open cardiovascular surgical procedure (carotid endarterectomy, arterial aneurysm or bypass surgery, or coronary artery bypass surgery) or a myocardial infarction within the 3 months prior to randomization
- Underwent a successful or partially successful endovascular intervention for peripheral arterial occlusive disease. (ie. Aorta, iliac, femoral, popliteal, or tibial artery angioplasty, stenting, or atherectomy) within the prior 3 months.
- Endovascular coronary intervention (ie. Angioplasty, atherectomy, stenting) within 1 month prior to randomization.
Underwent a failed attempt for endovascular revascularization during the prior 1 month. For the purpose of this exclusion criteria an endovascular procedure is considered a failure if:
- The procedure is diagnostic only with no intervention performed, (for example in the case where wire crossing can not be obtained).
- The treated artery recoils, thromboses, or dissects resulting in occlusion of the treated arterial segment, documented by intraoperative imaging. Note that endovascular procedures with suboptimal results but not meeting criteria 1 or 2 above may qualify for inclusion after 3 months as in #16 above.
- Cerebrovascular accident within 6 months prior to randomization.
- Treatment with topical growth factors or hyperbaric oxygen (HBO) within 30 days, or systemic growth factor treatment within 6 months of enrollment.
- Known hypersensitivity to heparin; or history of heparin-induced thrombocytopenia (HIT).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: BMAC Treatment
Intervention- Injection of 40 ml of autologous bone marrow concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
|
Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
|
Placebo Comparator: Placebo Injection
Injection of placebo (diluted peripheral blood) into ischemic tissue of the lower extremity
|
Injection of placebo into ischemic tissue of the lower extremity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amputation Free Survival
Time Frame: Six Months
|
Survival without a major (above the ankle) amputation
|
Six Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change In Rutherford Classification
Time Frame: Six Months
|
Change in the subjects clinical status as measured by Rutherford Classification
|
Six Months
|
Change in Pain
Time Frame: Six Months
|
Change in Subjects perception of pain as measured on a 100 mm visual analog scale
|
Six Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark Iafrati, MD, Tufts Medical Ctr
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLI-2011-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Limb Ischemia
-
R3 Vascular Inc.RecruitingCritical Limb Ischemia | Critical Lower Limb Ischemia | Critical Limb-Threatening IschemiaAustralia
-
Fudan UniversityActive, not recruiting
-
University Health Network, TorontoUnknown
-
Changi General HospitalCompletedCritical Limb IschemiaSingapore
-
AnGes USA, Inc.TerminatedCritical Limb IschemiaUnited States, France, Belgium, Canada, Poland, Finland, Denmark, Netherlands, Hungary, Italy, Sweden
-
R-BioPusan National University HospitalCompletedCritical Limb IschemiaKorea, Republic of
-
Pharmicell Co., Ltd.Withdrawn
-
Lifecells, LLC.CompletedCritical Limb IschemiaUnited States
-
Neuromed IRCCSUnknown
Clinical Trials on BMAC injection
-
Bone and Joint Clinic of Baton RougeActive, not recruitingDegenerative Disc Disease | Spine DegenerationUnited States
-
Harvest TechnologiesCompletedCongestive Heart FailureGermany, India, Peru
-
Harvest TechnologiesCompleted
-
University Hospital OstravaCompleted
-
Harvest TechnologiesCompletedArterial Occlusive DiseasesIndia
-
Massachusetts General HospitalRecruitingAcetabular Labrum Tear | Femoro Acetabular Impingement | Chondral Defect | Bone Marrow Aspirate Concentrate | Mesenchymal Stromal CellUnited States
-
Harvest TechnologiesUniversity of UtahTerminated
-
Nova Scotia Health AuthorityTerminated
-
Harvest TechnologiesTerminated
-
OhioHealthCompletedKnee OsteoarthritisUnited States